| scholarly article | Q13442814 |
| P50 | author | Ziad El-Zoghby | Q53180627 |
| P2093 | author name string | F G Cosio | |
| M D Stegall | |||
| J M Gloor | |||
| H Amer | |||
| D J Lager | |||
| W K Kremers | |||
| P2860 | cites work | Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause | Q43580802 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 527-535 | |
| P577 | publication date | 2008-02-03 | |
| P1433 | published in | American Journal of Transplantation | Q4744273 |
| P1476 | title | Identifying specific causes of kidney allograft loss | |
| P478 | volume | 9 |
| Q91874700 | A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection |
| Q49925863 | A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity |
| Q36371094 | A case of late kidney allograft failure: a clinical pathological conference from American Society of Nephrology Kidney Week 2011. |
| Q51559236 | A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy. |
| Q58747177 | A large, international study on post-transplant glomerular diseases: the TANGO project |
| Q39869686 | A molecular classifier for predicting future graft loss in late kidney transplant biopsies |
| Q64083486 | A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation |
| Q35835015 | A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers |
| Q39130806 | A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. |
| Q51766509 | ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. |
| Q38445336 | Achieving incompatible transplantation through desensitization: current perspectives and future directions |
| Q41946081 | Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis |
| Q38215262 | Acute and chronic antibody-mediated rejection in pediatric kidney transplantation |
| Q50995169 | Acute kidney injury as defined by the RIFLE criteria is a risk factor for kidney transplant graft failure. |
| Q52728730 | Allogeneic dendritic cells stimulated with antibodies against HLA class II polarize naive T cells in a follicular helper phenotype. |
| Q39829568 | An Integrated View of Molecular Changes, Histopathology and Outcomes in Kidney Transplants |
| Q33414342 | An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies |
| Q26827623 | An important role for autoimmunity in the immunopathogenesis of chronic allograft rejection |
| Q61945632 | Analysis of Specificity of Anti–Human Leukocyte Antigen Antibodies in Kidney Recipients in Reference to Clinical Outcome |
| Q34570605 | Analysis of machine perfusion benefits in kidney grafts: a preclinical study |
| Q40078116 | Angiosarcoma Developing in an Arteriovenous Fistula after Kidney Transplantation |
| Q36574775 | Angiotensin II blockade in kidney transplant recipients |
| Q35755581 | Anti-phospholipase A₂ receptor antibodies in recurrent membranous nephropathy |
| Q38130585 | Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies |
| Q96954772 | Approach and Management of Hypertension After Kidney Transplantation |
| Q35124252 | Association of early kidney allograft failure with preformed IgA antibodies to β2-glycoprotein I. |
| Q42722931 | Bad Memory: CD4 T Cell Presensitization Fosters Antibody-Mediated Kidney Transplant Rejection. |
| Q37058043 | Banff 2011 Meeting report: new concepts in antibody-mediated rejection |
| Q42395013 | Begin at the Beginning to Prevent the End. |
| Q90704764 | Being Overweight Is Related to Faster Decline in Annual Glomerular Filtration Rate in Kidney Transplant |
| Q48013543 | Belatacept Conversion in an HIV-Positive Kidney Transplant Recipient With Prolonged Delayed Graft Function |
| Q38044759 | Belatacept: a new era of immunosuppression? |
| Q41035928 | Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study |
| Q48785899 | Blood biomarkers of kidney transplant rejection, an endless search? |
| Q91260277 | CD56+CD57+ infiltrates as the most predominant subset of intragraft natural killer cells in renal transplant biopsies with antibody-mediated rejection |
| Q38116657 | Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence |
| Q38307029 | Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation |
| Q37464226 | Calcineurin inhibitors in HLA-identical living related donor kidney transplantation |
| Q36769749 | Calcineurin inhibitors: short-term friend, long-term foe? |
| Q39957158 | Can protocol biopsy better inform our choices in renal transplantation? |
| Q44593210 | Cardiac troponin T before and after kidney transplantation: determinants and implications for posttransplant survival. |
| Q36365811 | Challenges and considerations in diagnosing the kidney disease in deteriorating graft function |
| Q90685959 | Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years |
| Q48272314 | Characterization of ectopic lymphoid structures in different types of acute renal allograft rejection |
| Q34901573 | Characterization of transfusion-elicited acute antibody-mediated rejection in a rat model of kidney transplantation |
| Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
| Q44276263 | Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. |
| Q35929301 | Chronic progressive calcineurin nephrotoxicity: an overstated concept |
| Q38035660 | Chronic renal allograft injury: early detection, accurate diagnosis and management. |
| Q50879242 | Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development. |
| Q89915377 | Clinical Courses of Graft Failure Caused by Chronic Allograft Dysfunction in Kidney Transplantation |
| Q38076666 | Clinical and histological predictors of long-term kidney graft survival. |
| Q50966306 | Clinical and immunological features of very long-term survivors with a single renal transplant. |
| Q92553772 | Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes |
| Q33412327 | Clinical aspects: focusing on key unique organ-specific issues of renal transplantation |
| Q51262438 | Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. |
| Q37974480 | Clinical role of the renal transplant biopsy |
| Q26780271 | Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation |
| Q87491674 | Clinicopathologic characteristics and outcomes of late acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience |
| Q90734448 | Comparison of the effects of standard vs low-dose prolonged-release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts |
| Q26797336 | Computational Biology: Modeling Chronic Renal Allograft Injury |
| Q37811517 | Contribution of epithelial plasticity to renal transplantation-associated fibrosis |
| Q38241710 | Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients |
| Q47396102 | Correlation Between Renal Cortical Stiffness and Histological Determinants by Point Shear-Wave Elastography in Patients With Kidney Transplantation. |
| Q42238587 | Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation |
| Q38843499 | Current status of pediatric renal transplant pathology |
| Q50711738 | Cyclodextrin curcumin formulation improves outcome in a preclinical pig model of marginal kidney transplantation. |
| Q46938131 | DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant. |
| Q38861456 | De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients. |
| Q37802561 | De novo anti-HLA antibodies in renal allograft recipients: a cross-section study. |
| Q38590750 | Decade in review--renal transplantation: A spectrum of advances in renal transplantation |
| Q37097821 | Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10. |
| Q38569092 | Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection. |
| Q61946036 | Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant |
| Q57159271 | Development and future deployment of a five-year allograft survival model for kidney transplantation |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q34224452 | Diagnosis and prevention of chronic kidney allograft loss |
| Q90369056 | Differences in national and international guidelines regarding use of kidney stone formers as living kidney donors |
| Q82944257 | Different etiologies of graft loss and death in Asian kidney transplant recipients: a report from Thai Transplant Registry |
| Q35760445 | Differential Expression of Specific Dermatan Sulfate Domains in Renal Pathology |
| Q33530073 | Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats |
| Q35790585 | Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients. |
| Q37226086 | Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes? |
| Q33561691 | Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts |
| Q92803508 | Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure |
| Q88972270 | Donor-specific Antibody Surveillance and Graft Outcomes in Pediatric Kidney Transplant Recipients |
| Q50696120 | Dose-ranging study of the performance of the natural oxygen transporter HEMO2 Life in organ preservation. |
| Q26851294 | Dyslipidemia and its therapeutic challenges in renal transplantation |
| Q37346593 | Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study |
| Q34639731 | Early Steroid Withdrawal in Repeat Kidney Transplantation |
| Q54434558 | Early protocol biopsies in pediatric renal transplantation: interest for the adaptation of immunosuppression. |
| Q89965614 | Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts |
| Q53803179 | Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. |
| Q33879559 | Effect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective study |
| Q28076286 | Efficacy of Acute Cellular Rejection Treatment According to Banff Score in Kidney Transplant Recipients: A Systematic Review |
| Q41472979 | Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation |
| Q38786418 | Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation |
| Q36194753 | Emerging role of autophagy in kidney function, diseases and aging |
| Q42220901 | Enhanced posttransplant management of patients with diabetes improves patient outcomes |
| Q35108909 | Epithelial-to-mesenchymal transition predicts cyclosporine nephrotoxicity in renal transplant recipients |
| Q37992135 | Everolimus: preventing organ rejection in adult kidney transplant recipients |
| Q90418562 | Evidence for the alloimmune basis and prognostic significance of Borderline T cell-mediated rejection |
| Q92429175 | Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients |
| Q26825480 | Factors influencing long-term outcome after kidney transplantation |
| Q51876388 | Factors that may influence estimated glomerular filtration rate in patients with excellent graft function 10 years posttransplant. |
| Q55413815 | Fatal Pneumococcus Sepsis after Treatment of Late Antibody-Mediated Kidney Graft Rejection. |
| Q53570157 | Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. |
| Q34457101 | Fibrosis with inflammation at one year predicts transplant functional decline. |
| Q87268379 | Genetic determinants of renal transplant outcome: where do we stand? |
| Q47165108 | Glomerulocapillary miRNA response to HLA-class I antibody in vitro and in vivo. |
| Q91650815 | Graft failure of IgA nephropathy in renal allografts following living donor transplantation: predictive factor analysis of 102 biopsies |
| Q50562280 | HLA gene dosage effect on renal allograft survival. |
| Q40877005 | Hepatitis B virus, hepatitis C virus, and kidney transplant acute rejection and survival |
| Q64263307 | High Calcineurin Inhibitor Intrapatient Variability Is Associated With Renal Allograft Inflammation, Chronicity, and Graft Loss |
| Q36304550 | High Serum Level of β2-Microglobulin in Late Posttransplant Period Predicts Subsequent Decline in Kidney Allograft Function: A Preliminary Study |
| Q89547647 | High numbers of differentiated CD28null CD8+ T cells are associated with a lowered risk for late rejection and graft loss after kidney transplantation |
| Q38934802 | High-Throughput Proteomic Approaches to the Elucidation of Potential Biomarkers of Chronic Allograft Injury (CAI). |
| Q48005375 | Highly Immunogenic DQB1 Mismatch Eplets Are Associated With Development of Chronic Active Antibody-Mediated Rejection: A First Report From Japan |
| Q94673532 | Histologic Case Definition of an Atypical Glomerular Immune-Complex Deposition Following Kidney Transplantation |
| Q37964270 | Histology and proteinuria after renal transplantation |
| Q38154130 | Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation |
| Q36513609 | Human endometrial regenerative cells attenuate renal ischemia reperfusion injury in mice |
| Q38128162 | Hypertension after kidney transplantation: a pathophysiologic approach |
| Q37563822 | IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES. |
| Q37535280 | Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function |
| Q37813414 | Immune monitoring and biomarkers to predict chronic allograft dysfunction |
| Q38793766 | Immune monitoring in renal transplantation: The search for biomarkers |
| Q96303595 | Impact of Combinations of Donor and Recipient Ages and Other Factors on Kidney Graft Outcomes |
| Q40508719 | Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. |
| Q42740954 | Impact of acute rejection on kidney allograft outcomes in recipients on rapid steroid withdrawal |
| Q55205697 | Impact of the pretransplant dialysis modality on kidney transplantation outcomes: a nationwide cohort study. |
| Q85930804 | Impaired kidney allograft: how long can it function? A single-center study of the transplantation population |
| Q53425445 | Improving long-term renal allograft survival via a road less traveled by. |
| Q50848721 | Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. |
| Q40328463 | Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. |
| Q36824123 | Inflammation in the setting of chronic allograft dysfunction post-kidney transplant: phenotype and genotype |
| Q59799492 | Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury |
| Q38341632 | Innate immunity in solid organ transplantation: an update and therapeutic opportunities |
| Q39294056 | Interaction between castanospermine an immunosuppressant and cyclosporin A in rat cardiac transplantation |
| Q51002006 | Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study. |
| Q92120508 | Investigation of the Factors Affecting Allograft Kidney Functions: Results of 10 Years |
| Q35550570 | Isolated endarteritis and kidney transplant survival: a multicenter collaborative study |
| Q39035802 | Kidney Fibrosis: Origins and Interventions |
| Q51585363 | Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. |
| Q47786299 | Kidney allograft failure in the steroid-free immunosuppression era: A matched case-control study. |
| Q90474075 | Kidney allograft fibrosis: what we learned from latest translational research studies |
| Q51080659 | Kidney allograft function and histology in recipients dying with a functioning graft. |
| Q46211382 | Kidney allograft survival after acute rejection, the value of follow-up biopsies |
| Q41834576 | Late kidney dysfunction in a kidney transplant recipient |
| Q40181170 | Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept. |
| Q41189455 | Living-donor and Deceased-donor Renal Transplantation: Differences in Early Outcome--A Single-center Experience |
| Q64083260 | Long-Term Outcomes among Kidney Transplant Recipients and after Graft Failure: A Single-Center Cohort Study in Brazil |
| Q44355155 | Long-term allograft survival after kidney transplantation |
| Q35078258 | Long-term gene therapy with thrombospondin 2 inhibits TGF-β activation, inflammation and angiogenesis in chronic allograft nephropathy |
| Q40149564 | Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. |
| Q39000243 | Long-term survival (>25 years) of deceased donor kidney transplant recipients: a single-center experience |
| Q54372605 | Mammalian target of rapamycin signal inhibitors could play a role in the treatment of BK polyomavirus nephritis in renal allograft recipients. |
| Q36417863 | Markers of Endothelial-to-Mesenchymal Transition: Evidence for Antibody-Endothelium Interaction during Antibody-Mediated Rejection in Kidney Recipients |
| Q26740172 | Mechanisms and risk assessment of steroid resistance in acute kidney transplant rejection |
| Q38959093 | Membranous nephropathy in the kidney allograft |
| Q38742532 | Metabolomics Study for Identification of Potential Biomarkers of Long-term Survival in Kidney Transplantation Recipients |
| Q41001229 | Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study. |
| Q39313174 | Modernization of Chronic Allograft Injury Research: Better Biomarkers, Better Studies, Better Outcomes. |
| Q38458843 | Molecular Profile of Mitochondrial Dysfunction in Kidney Transplant Biopsies Is Associated With Poor Allograft Outcome. |
| Q38877380 | Molecular assessment of disease states in kidney transplant biopsy samples |
| Q38247310 | Molecular monitoring of alloimmune-mediated injury in kidney transplant patients |
| Q38773711 | Moving Biomarkers toward Clinical Implementation in Kidney Transplantation |
| Q38791651 | New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients |
| Q37898509 | New therapeutic approaches to antibody-mediated rejection in renal transplantation |
| Q90255868 | Non-HLA donor-recipient mismatches in kidney transplantation-A stone left unturned |
| Q35776842 | Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples - a multicentre phase 3 diagnostic accuracy study |
| Q85843781 | Noninvasive allograft imaging of acute rejection: evaluation of (131)I-anti-CXCL10 mAb |
| Q40198997 | Outcomes and Mortality in Renal Transplant Recipients Admitted to the Intensive Care Unit |
| Q64902782 | Pathological assessment of allograft nephrectomy: An Iranian experience. |
| Q47104714 | Pharmacologic Complement Inhibition in Clinical Transplantation. |
| Q38005448 | Phenotypes of antibody-mediated rejection in organ transplants |
| Q35932423 | Polyclonal Recipient nTregs Are Superior to Donor or Third-Party Tregs in the Induction of Transplantation Tolerance |
| Q38662974 | Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants. |
| Q47556851 | Polyoma virus nephropathy in kidney transplantation. |
| Q39207543 | Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation |
| Q40159121 | Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. |
| Q31056244 | Predicting Individual Renal Allograft Outcomes Using Risk Models with 1-Year Surveillance Biopsy and Alloantibody Data. |
| Q40631613 | Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels |
| Q43037627 | Prediction of chronic allograft nephropathy using classification trees |
| Q54361889 | Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. |
| Q89884914 | Pretransplant Donor-Specific Anti-HLA Antibodies and the Risk for Rejection-Related Graft Failure of Kidney Allografts |
| Q36417468 | Primary nonfunction of renal allograft secondary to acute oxalate nephropathy |
| Q41039243 | Prognostic Significance of 1-Year Serum Albumin Levels Within the Normal Range After Kidney Transplantation |
| Q39730031 | Progress in Desensitization of the Highly HLA Sensitized Patient |
| Q47102162 | Progression of Interstitial Fibrosis during the First Year after Deceased Donor Kidney Transplantation among Patients with and without Delayed Graft Function |
| Q39712114 | Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes |
| Q34483895 | Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure: An Observational Cohort Study |
| Q26751478 | Proteomics for rejection diagnosis in renal transplant patients: Where are we now? |
| Q36972412 | Quantitative podocyte parameters predict human native kidney and allograft half-lives |
| Q38674466 | Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation |
| Q54283965 | Rapamycin and CTLA4Ig synergize to induce stable mixed chimerism without the need for CD40 blockade. |
| Q39989120 | Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation. |
| Q28080994 | Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes |
| Q47193282 | Recurrence of primary glomerulonephritis: Review of the current evidence |
| Q93047764 | Recurrent and de novo Glomerulonephritis After Kidney Transplantation |
| Q60976642 | Recurrent membranoproliferative glomerulonephritis after kidney transplantation |
| Q96812462 | Reduced Recurrence of Primary IgA Nephropathy in Kidney Transplant Recipients Receiving Everolimus With Corticosteroid: A Retrospective, Single-Center Study of 135 Transplant Patients |
| Q38120752 | Regulatory T cells in the immunodiagnosis and outcome of kidney allograft rejection |
| Q64254119 | Regulatory T-cell Number in Peripheral Blood at 1 Year Posttransplant as Predictor of Long-term Kidney Graft Survival |
| Q41160324 | Relationships among injury, fibrosis, and time in human kidney transplants. |
| Q53103451 | Renal Allograft Histology at 10 Years After Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury. |
| Q52845695 | Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. |
| Q50543710 | Renal Consequences of Diabetes After Kidney Donation. |
| Q38359455 | Renal allograft fibrosis: biology and therapeutic targets |
| Q42343473 | Renal association clinical practice guideline in post-operative care in the kidney transplant recipient |
| Q51273191 | Resolution of low-grade proteinuria is associated with improved outcomes after renal transplantation-a retrospective longitudinal study. |
| Q39429916 | Risk factors and prognosis of late acute rejection in Chinese kidney transplant recipients. |
| Q57474736 | Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection |
| Q42687855 | Seasonality of mortality and graft failure among kidney transplant recipients in the US - a retrospective study. |
| Q58415922 | Severe infections requiring intensive care unit admission in kidney transplant recipients: impact on graft outcome |
| Q89449672 | Single-Cell Transcriptomics of a Human Kidney Allograft Biopsy Specimen Defines a Diverse Inflammatory Response |
| Q57069531 | Sleep disorders: Serious threats among kidney transplant recipients |
| Q46270370 | Soluble CD30 correlates with clinical but not subclinical renal allograft rejection |
| Q64285968 | Source and Relevance of the BK Polyomavirus Genotype for Infection After Kidney Transplantation |
| Q64992195 | Spontaneous resolution of acute T cell-mediated rejection in a renal transplant patient. |
| Q36281955 | Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation |
| Q88688862 | Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation |
| Q37601839 | Successful Treatment of Plasma Cell-Rich Acute Rejection Using Pulse Steroid Therapy Alone: A Case Report |
| Q51012535 | Supplementation with a new therapeutic oxygen carrier reduces chronic fibrosis and organ dysfunction in kidney static preservation. |
| Q47595221 | T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. |
| Q38148197 | T-cell co-stimulatory blockade in transplantation: two steps forward one step back! |
| Q53143416 | TIPE2, a novel biomarker for clinical chronic kidney allograft rejection. |
| Q28087131 | Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use |
| Q55307350 | Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. |
| Q41355218 | Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation |
| Q50211007 | Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil |
| Q43158421 | Tetrahydrobiopterin protects the kidney from ischemia-reperfusion injury |
| Q28087773 | The Complement System and Antibody-Mediated Transplant Rejection |
| Q99209009 | The Effect of Tacrolimus Trough Variability on Kidney Transplant Outcomes |
| Q38225882 | The Interplay between inflammation and fibrosis in kidney transplantation. |
| Q28554254 | The Spectrum of Renal Allograft Failure |
| Q36782862 | The Use of Genomics and Pathway Analysis in Our Understanding and Prediction of Clinical Renal Transplant Injury |
| Q93010157 | The cannabinoid receptor 1 is involved in renal fibrosis during chronic allograft dysfunction: Proof of concept |
| Q53186858 | The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. |
| Q38113083 | The impact of APOL1, CAV1, and ABCB1 gene variants on outcomes in kidney transplantation: donor and recipient effects |
| Q38112540 | The impact of calcineurin inhibitors on graft survival |
| Q85105199 | The impact of urinary tract infections in renal transplant recipients |
| Q89175508 | The influence of clinical, environmental, and socioeconomic factors on five-year patient survival after kidney transplantation |
| Q39812222 | The molecular phenotype of 6-week protocol biopsies from human renal allografts: reflections of prior injury but not future course. |
| Q38370826 | The need for minimization strategies: current problems of immunosuppression. |
| Q38630386 | The over-exaggerated chronic nephrotoxicity of calcineurin inhibitors |
| Q46000183 | The pathology and clinical features of early recurrent membranous glomerulonephritis. |
| Q37813404 | The pathology of chronic allograft dysfunction |
| Q54116671 | The prognostic values of caveolin-1 immunoreactivity in peritubular capillaries in patients with kidney transplantation. |
| Q38578386 | The safety of calcineurin inhibitors for kidney-transplant patients |
| Q38247690 | The significance of histological diagnosis in renal allograft biopsies in 2014. |
| Q48162490 | The time dependency of renal allograft histology |
| Q35658590 | The two kidney to one kidney transition and transplant glomerulopathy: a podocyte perspective |
| Q44522008 | Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients. |
| Q38237365 | Through a glass darkly: seeking clarity in preventing late kidney transplant failure |
| Q44535101 | Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure |
| Q89633687 | Torquetenovirus Serum Load and Long-Term Outcomes in Renal Transplant Recipients |
| Q38205229 | Transplant glomerulopathy: the interaction of HLA antibodies and endothelium |
| Q88355040 | Transplantation: Utilizing the transcriptome to predict allograft fibrosis |
| Q90745717 | Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching |
| Q47920746 | Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. |
| Q39410091 | Treatment of membranous nephropathy: time for a paradigm shift |
| Q40964596 | Urinary biomarkers of chronic allograft nephropathy. |
| Q89900024 | Urinary cell transcriptomics and acute rejection in human kidney allografts |
| Q50743724 | Using Molecular Phenotyping to Guide Improvements in the Histologic Diagnosis of T Cell-Mediated Rejection. |
| Q47822802 | Using omics to explore complications of kidney transplantation. |
| Q82770343 | [Nephrotoxicity of calcineurin inhibitors: presentation, diagnostic problems and risk factors] |
| Q38191482 | siRNA technology in kidney transplantation: current status and future potential |
Search more.